Anti-FMO3 antibody [EPR6968]
- RabMAb
- Recombinant
- 20ul selling size
- What is this?
4
(3 Reviews)
|
(17 Publications)
Rabbit Recombinant Monoclonal FMO3 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Mouse, Rat, Human samples. Cited in 17 publications.
View Alternative Names
Flavin-containing monooxygenase 3, Dimethylaniline monooxygenase [N-oxide-forming] 3, Dimethylaniline oxidase 3, FMO II, FMO form 2, Hepatic flavin-containing monooxygenase 3, Trimethylamine monooxygenase, FMO 3, FMO3
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-FMO3 antibody [EPR6968] (AB126711)
Immunocytochemistry/Immunofluorescence analysis of HepG2 cells labelling FMO3 with purified ab126711 at 1/150. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/500) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. ab7291, a mouse anti-tubulin (1/500) and ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/500) were also used.
Control 1 : primary antibody (1/100) and secondary antibody, ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/500).
Control 2 : ab7291 (1/1000) and secondary antibody, ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/500).
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FMO3 antibody [EPR6968] (AB126711)
Immunohistochemitsy (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling FMO3 with unpurified ab126711 at a 1/500 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FMO3 antibody [EPR6968] (AB126711)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling FMO3 with purified ab126711 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FMO3 antibody [EPR6968] (AB126711)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of rat liver tissue labelling FMO3 with purified ab126711 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FMO3 antibody [EPR6968] (AB126711)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of mouse liver tissue labelling FMO3 with purified ab126711 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.
- WB
Unknown
Western blot - Anti-FMO3 antibody [EPR6968] (AB126711)
Blocking and diluting buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-FMO3 antibody [EPR6968] (ab126711) at 1/5000 dilution
Lane 1:
Human fetal kidney tissue lysate at 20 µg
Lane 2:
Human fetal liver tissue lysate at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 60 kDa
Observed band size: 56 kDa
false
- WB
Unknown
Western blot - Anti-FMO3 antibody [EPR6968] (AB126711)
All lanes:
Western blot - Anti-FMO3 antibody [EPR6968] (ab126711) at 1/1000 dilution
Lane 1:
Human fetal liver tissue lysate at 10 µg
Lane 2:
Human fetal kidney tissue lysate at 10 µg
Secondary
All lanes:
HRP-conjugated goat anti-rabbit IgG at 1/2000 dilution
Predicted band size: 60 kDa
false
- WB
Unknown
Western blot - Anti-FMO3 antibody [EPR6968] (AB126711)
Blocking and diluting buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-FMO3 antibody [EPR6968] (ab126711) at 1/5000 dilution
Lane 1:
Mouse kidney tissue lysate at 20 µg
Lane 2:
Mouse liver tissue lysate at 20 µg
Lane 3:
Rat kidney tissue lysate at 20 µg
Lane 4:
Rat liver tissue lysate at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 60 kDa
Observed band size: 56 kDa
false
- OI-RD Scanning
Unknown
OI-RD Scanning - Anti-FMO3 antibody [EPR6968] (AB126711)
We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.
- WB
CiteAb
Western blot - Anti-FMO3 antibody [EPR6968] (AB126711)
FMO3 western blot using anti-FMO3 antibody [EPR6968] ab126711. Publication image and figure legend from Li, L., Chen, B., et al., 2019, Aging (Albany NY), PubMed 31715585.
ab126711 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab126711 please see the product overview.
Fructus Ligustri Lucidi (FLL) decreases the expression of FMO3 and the levels of circulating TMAO in aging mice. (A) The circulating TMAO levels quantified by LC/MS/MS. The expression levels of FMO3 were analyzed by immunohistochemical staining (B–C) and western blot (D) in the livers. (E–F) Correlation heat map indicating the association between the specific microbiota taxonomic genera and FMO3 expressions (E) and TMAO levels (F). Red indicates a positive association, blue denotes a negative association, and white manifests no association. a denotes a significant false discovery rate (FDR)-adjusted positive correlation at p values of < 0.05, and aa denotes a significant FDR-adjusted positive correlation at p values of < 0.01. b denotes a significant FDR-adjusted negative correlation at p values of < 0.05, and bb denotes a significant FDR-adjusted negative correlation at P values of < 0.01. Data are presented as mean ± SD. # compared with the normal group. * compared with the aging model group. p < 0.05 was considered statistical difference, n=8.
false
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (17)
Recent publications for all applications. Explore the full list and refine your search
Scientific reports 15:26035 PubMed40676134
2025
Applications
Unspecified application
Species
Unspecified reactive species
Genes 16: PubMed40282416
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 16:1515485 PubMed40098615
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in molecular neuroscience 17:1499591 PubMed39669439
2024
Applications
Unspecified application
Species
Unspecified reactive species
BMC oral health 24:1455 PubMed39614243
2024
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of clinical investigation 134: PubMed39480513
2024
Applications
Unspecified application
Species
Unspecified reactive species
Communications biology 7:1054 PubMed39191965
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cardiovascular diabetology 23:299 PubMed39143579
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of translational medicine 22:352 PubMed38622667
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 15:2526 PubMed38514666
2024
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com